By Josh Beckerman
Janux Therapeutics shares were up 12% after existing investor Avalon Ventures reported the purchase of 849,854 shares at $5.87 in a filing late Monday.
The stock was recently at $7.92 and is down about 39% this year.
In March 2021, the cancer-focused biopharmaceutical company announced the close of a $56 million Series A financing led by Avalon. Janux’s June 2021 initial public offering was priced at $17 per share.
Write to Josh Beckerman at [email protected]
Read the full article here